Ascendis Pharma A/S T.ASND

Primary Symbol: ASND

Healthcare Biotechnology

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

NDAQ:ASND - Post by User

Ascendis Pharma A/S

<< Previous

Bullboard Posts

Next >>

(31)
•••

Post by stockfyon Jul 12, 2024 6:02am

194 Views

Post# 36129706

ASND: Construction decision is the second half of 2024

The resident clown and frequent poster of this board a.k.a. 101724 alias, noted a few days ago:

"Didn't this clown show say they would have a decision about going ahead or not with the mine in June? "

The answer is NO.

ASND has stated that:

"In 2024 we look to build off these achievements as we work to further optimize the FS work to enhance the project value, continue exploration work outside of the North and South Zones to enhance the resource potential, receive our construction permits, and finalize a low-cost ECA project financing package ahead of a construction decision at Lagoa Salgada in 2H 2024. "

<< Previous

Bullboard Posts

Next >>

Cymat to acquire value-added tech from Rio Tinto